Published in Curr Diab Rep on June 01, 2003
Symptoms across the continuum of acute coronary syndromes: differences between women and men. Am J Crit Care (2008) 1.34
High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia (2012) 1.08
Increased prevalence of ventricular fibrillation in patients with type 2 diabetes mellitus. Heart Vessels (2007) 1.02
The role of G protein coupled receptor kinases in neurocardiovascular pathophysiology. Arch Med Sci (2012) 0.87
Impact of diabetes in patients with pulmonary hypertension. Pulm Circ (2015) 0.84
Early recognition of heart failure in patients with diabetes type 2 in primary care. A prospective diagnostic efficiency study. (UHFO-DM2). BMC Public Health (2009) 0.83
Gain of function of cardiac ryanodine receptor in a rat model of type 1 diabetes. Cardiovasc Res (2011) 0.83
The association of diabetes and older age with the absence of chest pain during acute coronary syndromes. West J Nurs Res (2008) 0.82
Should we treat prehypertension in diabetes? What are the cons? Diabetes Care (2009) 0.80
Subclinical Detection of Diabetic Cardiomyopathy with MicroRNAs: Challenges and Perspectives. J Diabetes Res (2015) 0.79
Exercise training: can it improve cardiovascular health in patients with type 2 diabetes? Br J Sports Med (2004) 0.77
Equilibrative Nucleoside Transporters 1 and 4: Which One Is a Better Target for Cardioprotection Against Ischemia-Reperfusion Injury? J Cardiovasc Pharmacol (2015) 0.75
Cost-effectiveness of screening strategies to detect heart failure in patients with type 2 diabetes. Cardiovasc Diabetol (2016) 0.75
Interactions between Diabetes and the Heart. J Diabetes Res (2016) 0.75
Metformin: an update. Ann Intern Med (2002) 5.62
Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med (2003) 4.08
Sleep duration among black and white Americans: results of the National Health Interview Survey. J Natl Med Assoc (2008) 3.82
Role of mitochondrial dysfunction in insulin resistance. Circ Res (2008) 3.45
Awareness of kidney disease and relationship to end-stage renal disease and mortality. Am J Med (2012) 2.24
Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis (2010) 2.18
Hypertension, angiotensin II, and oxidative stress. N Engl J Med (2002) 1.92
Mitochondrial biogenesis in the metabolic syndrome and cardiovascular disease. J Mol Med (Berl) (2010) 1.90
Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol (2004) 1.73
CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis (2008) 1.71
Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol (2007) 1.71
Bariatric surgery reduces visceral adipose inflammation and improves endothelial function in type 2 diabetic mice. Arterioscler Thromb Vasc Biol (2011) 1.69
Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link? Endocrine (2004) 1.64
Adverse effects of phytoestrogens on reproductive health: a report of three cases. Complement Ther Clin Pract (2008) 1.62
Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells. J Biol Chem (2006) 1.62
The case for low carbohydrate diets in diabetes management. Nutr Metab (Lond) (2005) 1.61
Effect of antihypertensive agents on the development of type 2 diabetes mellitus. Mayo Clin Proc (2006) 1.60
Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. Cardiovasc Diabetol (2005) 1.59
Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care (2002) 1.59
AT1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes: role of the AT1 receptor and NADPH oxidase. Hypertension (2003) 1.57
Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis (2009) 1.52
Control of blood pressure and other cardiovascular risk factors at different practice settings: outcomes of care provided to diabetic women compared to men. J Clin Hypertens (Greenwich) (2005) 1.51
ASH position paper: treatment of hypertension in patients with diabetes-an update. J Clin Hypertens (Greenwich) (2008) 1.50
Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy. Am J Geriatr Cardiol (2008) 1.48
Epidemiology of diabetes. J Clin Pharmacol (2004) 1.47
Angiotensin II-mediated oxidative stress promotes myocardial tissue remodeling in the transgenic (mRen2) 27 Ren2 rat. Am J Physiol Endocrinol Metab (2007) 1.46
Redox control of renal function and hypertension. Antioxid Redox Signal (2008) 1.45
Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease? Diabetes (2013) 1.45
Dietary carbohydrate restriction in type 2 diabetes mellitus and metabolic syndrome: time for a critical appraisal. Nutr Metab (Lond) (2008) 1.44
Skeletal muscle insulin resistance: role of inflammatory cytokines and reactive oxygen species. Am J Physiol Regul Integr Comp Physiol (2007) 1.39
Obstructive sleep apnea and cardiovascular disease: role of the metabolic syndrome and its components. J Clin Sleep Med (2008) 1.38
CKD and cardiovascular disease in screened high-risk volunteer and general populations: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis (2008) 1.37
Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-kappaB activation via NADPH oxidase. Am J Physiol Endocrinol Metab (2007) 1.36
Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression. Am J Physiol Endocrinol Metab (2004) 1.33
Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the Zucker obese rat. Hypertension (2010) 1.32
NADPH oxidase contributes to vascular inflammation, insulin resistance, and remodeling in the transgenic (mRen2) rat. Hypertension (2007) 1.32
Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Endocrinology (2007) 1.31
Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun (2003) 1.31
Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat. Am J Physiol Renal Physiol (2006) 1.30
The metabolic syndrome: role of skeletal muscle metabolism. Ann Med (2006) 1.28
Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance. Metabolism (2013) 1.27
Activation of mTOR/p70S6 kinase by ANG II inhibits insulin-stimulated endothelial nitric oxide synthase and vasodilation. Am J Physiol Endocrinol Metab (2011) 1.25
The role of oxidative stress in the metabolic syndrome. Rev Cardiovasc Med (2011) 1.23
Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment. Hypertension (2008) 1.23
Association of diabetes and hepatitis C infection: epidemiologic evidence and pathophysiologic insights. Curr Diab Rep (2004) 1.22
Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. Am J Physiol Endocrinol Metab (2008) 1.22
Molecular and metabolic mechanisms of cardiac dysfunction in diabetes. Life Sci (2012) 1.21
Renin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 rat. Endocrinology (2008) 1.21
Hypertension and obesity. Recent Prog Horm Res (2004) 1.20
Role of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord (2013) 1.19
Obesity and insulin resistance induce early development of diastolic dysfunction in young female mice fed a Western diet. Endocrinology (2013) 1.19
Differential regulation of angiotensin-(1-12) in plasma and cardiac tissue in response to bilateral nephrectomy. Am J Physiol Heart Circ Physiol (2009) 1.18
Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression. Endocrinology (2009) 1.18
The relationship between hyperinsulinemia, hypertension and progressive renal disease. J Am Soc Nephrol (2004) 1.16
Calciphylaxis: calcific uremic arteriolopathy and the emerging role of sodium thiosulfate. Int Urol Nephrol (2008) 1.16
Prevalence and associations of anemia of CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis (2008) 1.16
Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats. Endocrinology (2013) 1.15
Effect of renin inhibition and AT1R blockade on myocardial remodeling in the transgenic Ren2 rat. Am J Physiol Endocrinol Metab (2008) 1.15
Sleep duration and the risk of diabetes mellitus: epidemiologic evidence and pathophysiologic insights. Curr Diab Rep (2010) 1.14
The central role of vascular extracellular matrix and basement membrane remodeling in metabolic syndrome and type 2 diabetes: the matrix preloaded. Cardiovasc Diabetol (2005) 1.14
The renin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress. Med Clin North Am (2009) 1.13
Salt, aldosterone, and insulin resistance: impact on the cardiovascular system. Nat Rev Cardiol (2010) 1.13
Diabetes mellitus in CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition and Examination Survey (NHANES) 1999-2004. Am J Kidney Dis (2008) 1.12
Oxidative stress contributes to pulmonary hypertension in the transgenic (mRen2)27 rat. Am J Physiol Heart Circ Physiol (2008) 1.12
Adaptive mechanisms to compensate for overnutrition-induced cardiovascular abnormalities. Am J Physiol Regul Integr Comp Physiol (2011) 1.12
Oxidative stress, glucose metabolism, and the prevention of type 2 diabetes: pathophysiological insights. Antioxid Redox Signal (2007) 1.12
Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Prog Cardiovasc Dis (2010) 1.12
IGF-I alleviates diabetes-induced RhoA activation, eNOS uncoupling, and myocardial dysfunction. Am J Physiol Regul Integr Comp Physiol (2008) 1.11
Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, decreases cardiac oxidative stress and remodeling in Ren2 transgenic rats. Endocrinology (2007) 1.11
Hypertension in obesity. Med Clin North Am (2011) 1.10
Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol (2003) 1.09
Diabetes insipidus: diagnosis and treatment of a complex disease. Cleve Clin J Med (2006) 1.08
Insulin resistance and heart failure: molecular mechanisms. Heart Fail Clin (2012) 1.07
The role of tissue Renin-Angiotensin-aldosterone system in the development of endothelial dysfunction and arterial stiffness. Front Endocrinol (Lausanne) (2013) 1.06
Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats. J Hepatol (2008) 1.06
Attenuation of endocrine-exocrine pancreatic communication in type 2 diabetes: pancreatic extracellular matrix ultrastructural abnormalities. J Cardiometab Syndr (2008) 1.06
Isletopathy in Type 2 diabetes mellitus: implications of islet RAS, islet fibrosis, islet amyloid, remodeling, and oxidative stress. Antioxid Redox Signal (2007) 1.05
Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat. Am J Physiol Renal Physiol (2009) 1.04
National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. Kidney Int (2010) 1.04
Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system. Am J Physiol Heart Circ Physiol (2014) 1.04
Angiotensin II activation of mTOR results in tubulointerstitial fibrosis through loss of N-cadherin. Am J Nephrol (2011) 1.03
Nebivolol attenuates redox-sensitive glomerular and tubular mediated proteinuria in obese rats. Endocrinology (2010) 1.03
Oxidative stress in the cardiorenal metabolic syndrome. Curr Hypertens Rep (2012) 1.02
Mineralocorticoid receptor blockade improves diastolic function independent of blood pressure reduction in a transgenic model of RAAS overexpression. Am J Physiol Heart Circ Physiol (2011) 1.02
Nebivolol reduces proteinuria and renal NADPH oxidase-generated reactive oxygen species in the transgenic Ren2 rat. Am J Nephrol (2009) 1.02
The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich) (2005) 1.02
Obesity, cardiometabolic syndrome, and chronic kidney disease: the weight of the evidence. Adv Chronic Kidney Dis (2006) 1.01
Stroke in patients with diabetes and hypertension. J Clin Hypertens (Greenwich) (2005) 1.01
Overweight female rats selectively breed for low aerobic capacity exhibit increased myocardial fibrosis and diastolic dysfunction. Am J Physiol Heart Circ Physiol (2012) 1.01
Antiepileptic drugs and bone metabolism. Nutr Metab (Lond) (2006) 1.01
Albumin activation of NAD(P)H oxidase activity is mediated via Rac1 in proximal tubule cells. Am J Nephrol (2007) 1.01